Exelixis Total Assets 2006-2021 | EXEL

Exelixis total assets from 2006 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Exelixis total assets for the quarter ending September 30, 2021 were $2.448B, a 15.95% increase year-over-year.
  • Exelixis total assets for 2020 were $2.137B, a 13.35% increase from 2019.
  • Exelixis total assets for 2019 were $1.886B, a 32.58% increase from 2018.
  • Exelixis total assets for 2018 were $1.422B, a 117.05% increase from 2017.
Exelixis Annual Total Assets
(Millions of US $)
2020 $2,137
2019 $1,886
2018 $1,422
2017 $655
2016 $596
2015 $332
2014 $323
2013 $503
2012 $721
2011 $393
2010 $361
2009 $343
2008 $402
2007 $412
2006 $395
2005 $333
Exelixis Quarterly Total Assets
(Millions of US $)
2021-09-30 $2,448
2021-06-30 $2,367
2021-03-31 $2,191
2020-12-31 $2,137
2020-09-30 $2,111
2020-06-30 $2,047
2020-03-31 $1,956
2019-12-31 $1,886
2019-09-30 $1,785
2019-06-30 $1,643
2019-03-31 $1,542
2018-12-31 $1,422
2018-09-30 $1,024
2018-06-30 $911
2018-03-31 $775
2017-12-31 $655
2017-09-30 $610
2017-06-30 $517
2017-03-31 $587
2016-12-31 $596
2016-09-30 $548
2016-06-30 $477
2016-03-31 $493
2015-12-31 $332
2015-09-30 $363
2015-06-30 $249
2015-03-31 $283
2014-12-31 $323
2014-09-30 $384
2014-06-30 $441
2014-03-31 $498
2013-12-31 $503
2013-09-30 $556
2013-06-30 $612
2013-03-31 $660
2012-12-31 $721
2012-09-30 $763
2012-06-30 $374
2012-03-31 $413
2011-12-31 $393
2011-09-30 $412
2011-06-30 $454
2011-03-31 $496
2010-12-31 $361
2010-09-30 $373
2010-06-30 $420
2010-03-31 $284
2009-12-31 $343
2009-09-30 $421
2009-06-30 $333
2009-03-31 $355
2008-12-31 $402
2008-09-30 $255
2008-06-30 $317
2008-03-31 $371
2007-12-31 $412
2007-09-30 $420
2007-06-30 $372
2007-03-31 $421
2006-12-31 $395
2006-09-30 $271
2006-06-30 $306
2006-03-31 $338
2005-12-31 $333
2005-09-30 $339
2005-06-30 $325
2005-03-31 $270
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.189B $0.988B
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $121.969B 7.71
Bio-Rad Laboratories (BIO.B) United States $22.443B 45.55
QIAGEN (QGEN) Netherlands $12.359B 20.93
Biohaven Pharmaceutical Holding (BHVN) United States $7.214B 0.00
Arcus Biosciences (RCUS) United States $3.030B 0.00
Emergent Biosolutions (EBS) United States $2.347B 8.44
ADC Therapeutics SA (ADCT) Switzerland $1.505B 0.00
Myovant Sciences (MYOV) United Kingdom $1.429B 0.00
Zymeworks (ZYME) Canada $0.942B 0.00
Ambrx Biopharma (AMAM) United States $0.366B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09